VALENCIA , Calif., March 4 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the fourth quarter and year ended December 31, 2007 .
For the fourth quarter of 2007, total operating expenses were $79.1 million , compared to $71.8 million for the fourth quarter of 2006. Research and development (R&D) expenses increased by $7.0 million to $66.8 million for the fourth quarter of 2007 compared to the fourth quarter of 2006, primarily due to increased manufacturing costs (including clinical supplies) for Technosphere Insulin, offset in part by lower purchased services in the associated clinical development program. General and administrative (G&A) expenses increased by $0.3 million to $12.3 million for the fourth quarter of 2007 compared to the fourth quarter of 2006.
The net loss applicable to common stockholders for the fourth quarter of 2007 was $75.0 million , or $0.75 per share based on 99.6 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $71.3 million , or $1.30 per share based on 54.7 million weighted average shares outstanding, for the fourth quarter of 2006.
For the year ended December 31, 2007 , total operating expenses were $307.4 million , compared with $233.8 million for 2006. R&D expenses were $256.8 million in 2007, up $65.0 million from 2006, primarily related to increases in manufacturing costs (including clinical supplies) for Technosphere Insulin and associated clinical development program expenses. G&A expenses increased by $8.5 million to $50.5 million for 2007 as compared to 2006 primarily due to costs associated with an increased number of employees and increased professional fees. The total number of employees increased from 545 at the end of 2006 to 609 at the end of 2007.
The net loss applicable to common stockholders for 2007 was $293.2 million , or $3.66 per share based on 80.0 million weighted average shares outstanding, compared with a net loss applicable to common stockholders of $230.5 million , or $4.52 per share based on 51.0 million weighted averages shares outstanding for 2006. The number of common shares outstanding at December 31, 2007 was 101,380,823.
Cash, cash equivalents and marketable securities were $368.3 million at December 31, 2007 , $204.2 million at September 30, 2007 , and $436.5 million at December 31, 2006 . On October 5, 2007 , the Company received $250 million in gross proceeds from its self managed registered direct offering of approximately 27 million shares of common stock.
'During this past year, we made excellent progress toward our goal of
bringing Technosphere Insulin to market,' stated
Conference Call
MannKind management will host a conference call to discuss these results today at 9:00 a.m. ET . To participate in the call, please dial (888) 566-5775 or (210) 234-0004. To listen to the call via the internet, please visit http://www.mannkindcorp.com. The web site replay will be available for 14 days. A telephone replay will be accessible for approximately 14 days following completion of the call by dialing (866) 396-7637 or (203) 369-0522.
Presenting from the Company will be:
-- Chairman and Chief Executive Officer Alfred Mann
-- President and Chief Operating Officer Hakan Edstrom
-- Corporate Vice President and Chief Financial Officer Dick Anderson
-- Corporate Vice President and Chief Scientific Officer Peter Richardson
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Its lead product, the Technosphere(R) Insulin System, is currently in Phase 3 clinical trials in the United States , Europe and Latin America to study its safety and efficacy in the treatment of diabetes. For more information on MannKind Corporation and its technology, visit http://www.mannkindcorp.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to differentiating Technosphere Insulin from other insulins. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'intend,' 'will,' 'goal,' 'potential' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon MannKind's current expectations and involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the progress, timing and results of clinical trials, difficulties or delays in seeking or obtaining regulatory approval, and other risks detailed in MannKind's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2006 and periodic reports on Form 10-Q and Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and MannKind undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
(Tables to follow)
MannKind Corporation
Consolidated Statements of Operations
(Unaudited)
(In thousands, except Three Months Ended Year Ended
per share amounts) December 31, December 31,
2007 2006 2007 2006
Revenue $- $- $10 $100
Operating expenses:
Research and
development 66,751 59,740 256,844 191,796
General and
administrative 12,316 12,058 50,523 42,001
Total operating
expenses 79,067 71,798 307,367 233,797
Loss from operations (79,067) (71,798) (307,357) (233,697)
Other (expense) /
income (355) 48 (197) 208
Interest expense on
note payable to
principal stockholder - (822) - (1,511)
Interest expense on
convertible debt (584) (222) (3,408) (222)
Interest income 4,996 1,526 17,775 4,679
Loss before provision
for income taxes (75,010) (71,268) (293,187) (230,543)
Income taxes (3) - (3) (5)
Net loss applicable to
common stockholders $(75,013) $(71,268) $(293,190) $(230,548)
Net loss per share
applicable to common
stockholders - basic
and diluted $(0.75) $(1.30) $(3.66) $(4.52)
Shares used to compute
basic and diluted net
loss per share
applicable to common
stockholders 99,605 54,684 80,038 50,970
MannKind Corporation
Condensed Balance Sheet
(Unaudited)
(in thousands)
December 31, December 31,
Assets 2007 2006
Current assets:
Cash and cash equivalents $368,285 $319,555
Marketable securities - 116,924
State research and development tax credit
exchange receivable -- current 831 2,418
Prepaid expenses and other current assets 9,596 10,650
Total current assets 378,712 449,547
Property and equipment -- net 162,683 88,328
State research and development tax credit
exchange receivable -- net of current
portion 1,500 1,500
Other assets 548 362
Total $543,443 $539,737
Liabilities and Stockholders' Equity
Current liabilities $67,558 $44,959
Other liabilities 24 24
Senior convertible notes 111,761 111,267
Stockholders' equity 364,100 383,487
Total $543,443 $539,737
SOURCE MannKind Corporation
